ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Study Suggests “Bad Energy” is Core Problem in Fibromyalgia and Chronic Fatigue Syndrome (ME/CFS)

Travel Tips for the Chronically Ill

One of Our Strongest Allies Needs Our Help! Please read!

The Genetic Mutation That May Compromise Your Health - And What to Do About It

The Doctors and Mr. Hyde: Amy Brown’s M.E Enterovirus Story

Getting Clear on Ketogenic Diets (for Fibromyalgia and ME/CFS): A Review

Endogenous Pain Facilitation Rather Than Inhibition Differs Between People with Chronic Fatigue Synd...

ME/CFS Research Community Surprises: Submits Ten Research Center Applications to NIH

Making Music – and a Difference – for ME/CFS

The Scientist, the Seahorse and the Nanoneedle – Catching Up with Ron Davis on ME/CFS

 
Print Page
Email Article

Impact of a Pregabalin Step Therapy Policy Among Medicare Advantage Beneficiaries

  [ 1 vote ]   [ Discuss This Article ]
By Brandon T. Suehs PharmD, PhD, et al. • www.ProHealth.com • May 26, 2013


Abstract:

BACKGROUND: Managed healthcare organizations often utilize formulary management strategies such as prior authorization and step therapy to guide appropriate medication use and to control medication expenditures. The objective of this study was to examine clinical and economic outcomes associated with implementation of a pregabalin step therapy (ST) policy among Medicare Advantage Prescription Drug (MAPD) members.

METHODS: Pharmacy and medical claims data from Humana (restricted cohort; ST policy implemented 01/01/2009) and Thomson Reuters MarketScan® (unrestricted cohort) were analyzed for MAPD members aged 65 to 89  years receiving treatment for painful diabetic peripheral neuropathy (pDPN), postherpetic neuralgia (PHN) or fibromyalgia (FM). Difference-in-differences (DID) was used to examine year-over-year changes in disease-related and all-cause utilization and costs. Regression analyses examined medication utilization and healthcare expenditures after controlling for between-group compositional differences.

RESULTS: We identified 13,911 members in the restricted cohort and matched to members from unrestricted health plans. FM (51.0%) and pDPN (41.8%) were the most common diagnoses. Members in the unrestricted cohort were older and had a greater level of comorbidity than members in the restricted cohort. The restricted cohort demonstrated greater year-over-year decrease in pregabalin utilization and increase in year-over-year gabapentin utilization compared with the unrestricted cohort. ST restriction was associated with an increase in disease-related pharmacy costs and a decrease in total medical costs for the restricted cohort compared with the unrestricted cohort. There was no difference between cohorts in total healthcare cost.

CONCLUSION: After controlling for differences in age and comorbidity burden between the groups, implementation of a pregabalin ST restriction was associated with increased disease-related pharmacy costs and decreased total medical costs; however, there was no net difference in total healthcare cost or total pharmacy cost.

Source: Pain Practice, May 23, 2013. By Brandon T. Suehs PharmD, PhD, Anthony Louder RPh, PhD, Margarita Udall MPH, Joseph C. Cappelleri MPH, PhD, Ashish V. Joshi PhD, and Nick C. Patel PharmD, PhD. Competitive Health Analytics Inc., Louisville, Kentucky, U.S.A.





Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg MitoQ®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness

Natural Remedies

Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep? Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep?
Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love
How to Jump-start and Sustain Energy Production in CFS How to Jump-start and Sustain Energy Production in CFS
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map